Understand the source comparison
Peptides Help With Acne Scars—Comparison of Evidence-Backed Compounds
Before selecting a peptide protocol, understand how the major classes differ in mechanism, evidence strength, and suitability for specific scar subtypes. Copper Peptide (GHK-Cu) TGF- pathway activation, lysyl oxidase stimulation, MMP regulation RCT: 17–23% de
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understand how the major classes differ in mechanism, evidence strength, and suitability for specific scar subtypes.
- Copper Peptide (GHK-Cu)
- TGF-β pathway activation, lysyl oxidase stimulation, MMP regulation
- RCT: 17–23% depth reduction in atrophic scars over 12 weeks (J Cosmet Dermatol 2023)
- Atrophic (ice pick, rolling, boxcar)
- 0.5–2% in serum
- Strongest clinical evidence—gold standard for post-inflammatory atrophic scarring
- Palmitoyl Pentapeptide-4 (Matrixyl)
- Matrikine mimicry, procollagen I/III upregulation, TIMP expression
- RCT: 14% improvement in rolling scars over 16 weeks (Dermatol Surg 2021)
- Rolling, shallow boxcar
- 3–8% in cream/serum
- Solid evidence but slower results—best combined with copper peptides
- Tripeptide-1
- Collagen fragment signaling
- In-vitro only—no human scar trials published
- Unknown
- 2–5%
- Insufficient evidence—avoid until clinical data emerges
- Acetyl Hexapeptide-8 (Argireline)
- Neurotransmitter inhibition (SNARE complex disruption)
- None—mechanism irrelevant to static scars
- Not applicable
- 5–10%
- Wrong mechanism for acne scars—targets dynamic wrinkles, not collagen structure